172 related articles for article (PubMed ID: 28608404)
1. Apoptotic intrinsic pathway proteins predict survival in canine cutaneous mast cell tumours.
Barra CN; Macedo BM; Cadrobbi KG; Pulz LH; Huete GC; Kleeb SR; Xavier JG; Catão-Dias JL; Nishiya AT; Fukumasu H; Strefezzi RF
Vet Comp Oncol; 2018 Mar; 16(1):E38-E44. PubMed ID: 28608404
[TBL] [Abstract][Full Text] [Related]
2. The value of immunohistochemical expression of BAX in formulating a prognosis for canine cutaneous mast cell tumours.
Strefezzi Rde F; Kleeb SR; Xavier JG; Fukumasu H; Catão-Dias JL
J Comp Pathol; 2012 May; 146(4):314-9. PubMed ID: 21899858
[TBL] [Abstract][Full Text] [Related]
3. Expression of Ki67, BCL-2, and COX-2 in canine cutaneous mast cell tumors: association with grading and prognosis.
Vascellari M; Giantin M; Capello K; Carminato A; Morello EM; Vercelli A; Granato A; Buracco P; Dacasto M; Mutinelli F
Vet Pathol; 2013 Jan; 50(1):110-21. PubMed ID: 22673539
[TBL] [Abstract][Full Text] [Related]
4. All subunits of the interleukin-2 receptor are expressed by canine cutaneous mast cell tumours.
Meyer A; Gruber AD; Klopfleisch R
J Comp Pathol; 2013 Jul; 149(1):19-29. PubMed ID: 23276382
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of immunohistochemical markers in canine cutaneous mast cell tumours: A systematic review and meta-analysis.
Freytag JO; Queiroz MR; Govoni VM; Pereira IVA; Pulz LH; de Francisco Strefezzi R; Queiroga FL; Cogliati B
Vet Comp Oncol; 2021 Sep; 19(3):529-540. PubMed ID: 33724647
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Ki67, Bax, Bcl-2 and KIT in canine cutaneous mast cell tumours and their relationship with histopathology and prognosis.
Aytemiz Danyer I; Gürel A
Acta Vet Hung; 2024 Jan; 71(3-4):183-192. PubMed ID: 38112689
[TBL] [Abstract][Full Text] [Related]
7. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors.
Kiupel M; Webster JD; Kaneene JB; Miller R; Yuzbasiyan-Gurkan V
Vet Pathol; 2004 Jul; 41(4):371-7. PubMed ID: 15232137
[TBL] [Abstract][Full Text] [Related]
8. An immunohistochemical study of vitamin D receptor expression in canine cutaneous mast cell tumours.
Russell DS; Rassnick KM; Erb HN; Vaughan MM; McDonough SP
J Comp Pathol; 2010; 143(2-3):223-6. PubMed ID: 20334872
[TBL] [Abstract][Full Text] [Related]
9. Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication.
Webster JD; Yuzbasiyan-Gurkan V; Miller RA; Kaneene JB; Kiupel M
Vet Pathol; 2007 May; 44(3):298-308. PubMed ID: 17491070
[TBL] [Abstract][Full Text] [Related]
10. c-KIT messenger RNA and protein expression and mutations in canine cutaneous mast cell tumors: correlations with post-surgical prognosis.
Giantin M; Vascellari M; Morello EM; Capello K; Vercelli A; Granato A; Lopparelli RM; Nassuato C; Carminato A; Martano M; Mutinelli F; Dacasto M
J Vet Diagn Invest; 2012 Jan; 24(1):116-26. PubMed ID: 22362941
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical Expression of the Pluripotency Factor OCT4 in Canine Mast Cell Tumours.
Vargas TH; Pulz LH; Barra CN; Kleeb SR; Xavier JG; Catão-Dias JL; Fukumasu H; Nishiya AT; Strefezzi RF
J Comp Pathol; 2015 Nov; 153(4):251-5. PubMed ID: 26460092
[TBL] [Abstract][Full Text] [Related]
12. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours.
Kiupel M; Webster JD; Miller RA; Kaneene JB
J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):280-6. PubMed ID: 16050909
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and prognostic value of c-kit and TP53 mutations in canine mast cell tumours.
Vozdova M; Kubickova S; Fictum P; Fröhlich J; Jelinek F; Rubes J
Vet J; 2019 May; 247():71-74. PubMed ID: 30971355
[TBL] [Abstract][Full Text] [Related]
14. C-kit as a prognostic and therapeutic marker in canine cutaneous mast cell tumours: From laboratory to clinic.
Gil da Costa RM
Vet J; 2015 Jul; 205(1):5-10. PubMed ID: 26021891
[TBL] [Abstract][Full Text] [Related]
15. Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: a retrospective cohort study.
Takeuchi Y; Fujino Y; Watanabe M; Takahashi M; Nakagawa T; Takeuchi A; Bonkobara M; Kobayashi T; Ohno K; Uchida K; Asano K; Nishimura R; Nakayama H; Sugano S; Ohashi Y; Tsujimoto H
Vet J; 2013 Jun; 196(3):492-8. PubMed ID: 23384436
[TBL] [Abstract][Full Text] [Related]
16. Histologic grading of canine mast cell tumor: is 2 better than 3?
Sabattini S; Scarpa F; Berlato D; Bettini G
Vet Pathol; 2015 Jan; 52(1):70-3. PubMed ID: 24513799
[TBL] [Abstract][Full Text] [Related]
17. Differences in the proteome of high-grade versus low-grade canine cutaneous mast cell tumours.
Schlieben P; Meyer A; Weise C; Bondzio A; Einspanier R; Gruber AD; Klopfleisch R
Vet J; 2012 Nov; 194(2):210-4. PubMed ID: 22578690
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and Prognosis of Canine Cutaneous Mast Cell Tumors.
Kiupel M; Camus M
Vet Clin North Am Small Anim Pract; 2019 Sep; 49(5):819-836. PubMed ID: 31178200
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Canine Mast Cell Tumor Mortality Risk Based on Clinical, Histologic, Immunohistochemical, and Molecular Features.
Horta RS; Lavalle GE; Monteiro LN; Souza MCC; Cassali GD; Araújo RB
Vet Pathol; 2018 Mar; 55(2):212-223. PubMed ID: 29338615
[TBL] [Abstract][Full Text] [Related]
20. Comparison of serum tryptase as a diagnostic oncological marker in canine versus human mast cell neoplasms.
De Vos S; Demeyere K; De Cock H; Devriendt N; Schwarzkopf I; Fortrie R; Roggeman T; Meyer E; De Spiegelaere W; de Rooster H
Res Vet Sci; 2022 Dec; 151():90-95. PubMed ID: 35872552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
